Figure 2. Disease free survival from date of diagnosis Hre2 by immunohistochemistry (IHC 3+): (A) for patients treating with trastuzumab(B) patients treating without trastuzumab

From

Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran

Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi, Anita Kabir koohian

American Journal of Cancer Prevention. 2014, 2(2), 37-41 doi:10.12691/ajcp-2-2-4